EA201591019A1 - СПОСОБ СНИЖЕНИЯ КОЛИЧЕСТВА АМИЛОИДНЫХ БЛЯШЕК В ГОЛОВНОМ МОЗГЕ ПРИ ПОМОЩИ АНТИ-Aβ АНТИТЕЛ - Google Patents

СПОСОБ СНИЖЕНИЯ КОЛИЧЕСТВА АМИЛОИДНЫХ БЛЯШЕК В ГОЛОВНОМ МОЗГЕ ПРИ ПОМОЩИ АНТИ-Aβ АНТИТЕЛ

Info

Publication number
EA201591019A1
EA201591019A1 EA201591019A EA201591019A EA201591019A1 EA 201591019 A1 EA201591019 A1 EA 201591019A1 EA 201591019 A EA201591019 A EA 201591019A EA 201591019 A EA201591019 A EA 201591019A EA 201591019 A1 EA201591019 A1 EA 201591019A1
Authority
EA
Eurasian Patent Office
Prior art keywords
brain
antibody
reducing
antigen
amyloid
Prior art date
Application number
EA201591019A
Other languages
English (en)
Inventor
Тьерри Бюсье
Пол Х. Вейнреб
Томас Энгбер
Кеннет Роудс
Джозеф Арндт
Фан Цянь
Роберт В. Дунстан
Шайлендра Пател
Ян Гримм
Марсель Майер
Original Assignee
Байоджен Интернэшнл Нейросайенз Гмбх
Нейриммьюн Холдинг Аг
Тьерри Бюсье
Пол Х. Вейнреб
Томас Энгбер
Кеннет Роудс
Джозеф Арндт
Фан Цянь
Роберт В. Дунстан
Шайлендра Пател
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Интернэшнл Нейросайенз Гмбх, Нейриммьюн Холдинг Аг, Тьерри Бюсье, Пол Х. Вейнреб, Томас Энгбер, Кеннет Роудс, Джозеф Арндт, Фан Цянь, Роберт В. Дунстан, Шайлендра Пател filed Critical Байоджен Интернэшнл Нейросайенз Гмбх
Publication of EA201591019A1 publication Critical patent/EA201591019A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Данное изобретение относится к применению анти-Аβ антитела или его антигенсвязывающего фрагмента для снижения количества амилоидных бляшек в головном мозге или минимизации возникновения микрокровоизлияний при постоянном дозировании анти-Аβ антителом или его антигенсвязывающим фрагментом. Например, изобретение относится к способу снижения количества амилоидных бляшек в головном мозге, включающему введение субъекту анти-Аβ антитела или его антигенсвязывающего фрагмента, которое связывается с тем же самым эпитопом, что и антитело ВПВ037, при этом введение приводит к снижению количества амилоидных бляшек в головном мозге, не оказывая влияние на сосудистый амилоид, а антитело ВПВ037 связывается с эпитопом, содержащим аминокислоты 3-6 Аβ.
EA201591019A 2012-12-07 2013-12-06 СПОСОБ СНИЖЕНИЯ КОЛИЧЕСТВА АМИЛОИДНЫХ БЛЯШЕК В ГОЛОВНОМ МОЗГЕ ПРИ ПОМОЩИ АНТИ-Aβ АНТИТЕЛ EA201591019A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734799P 2012-12-07 2012-12-07
US201361773794P 2013-03-06 2013-03-06
PCT/US2013/073700 WO2014089500A1 (en) 2012-12-07 2013-12-06 A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES

Publications (1)

Publication Number Publication Date
EA201591019A1 true EA201591019A1 (ru) 2015-11-30

Family

ID=50884049

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591019A EA201591019A1 (ru) 2012-12-07 2013-12-06 СПОСОБ СНИЖЕНИЯ КОЛИЧЕСТВА АМИЛОИДНЫХ БЛЯШЕК В ГОЛОВНОМ МОЗГЕ ПРИ ПОМОЩИ АНТИ-Aβ АНТИТЕЛ

Country Status (13)

Country Link
US (1) US20150315267A1 (ru)
EP (1) EP2928494A4 (ru)
JP (1) JP2016501247A (ru)
KR (1) KR20150127570A (ru)
CN (1) CN105979962A (ru)
AU (1) AU2013354968A1 (ru)
BR (1) BR112015013312A2 (ru)
CA (1) CA2894178A1 (ru)
EA (1) EA201591019A1 (ru)
HK (1) HK1215673A1 (ru)
IL (1) IL239259A0 (ru)
MX (1) MX2015007147A (ru)
WO (1) WO2014089500A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN105616405B (zh) * 2014-11-05 2021-05-07 中国人民解放军第三军医大学第三附属医院 依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3322985B1 (en) * 2015-07-15 2021-10-13 Gestvision, Inc. Device for detecting misfolded proteins and methods of use thereof
EP3325506A1 (en) * 2015-07-21 2018-05-30 BioArctic AB Method for treatment of traumatic brain injury targeting aggregated peptides
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
CA3003435A1 (en) 2015-10-28 2017-05-04 The Trustees Of The University Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP2019517540A (ja) * 2016-06-07 2019-06-24 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー アルツハイマー病を治療する方法
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
MX2020001855A (es) * 2017-08-22 2020-08-13 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
EP3801618A4 (en) 2018-05-30 2022-07-27 National Health Research Institutes ANTI-ABETA ANTIBODIES AND USES THEREOF
AU2020395611A1 (en) * 2019-12-03 2022-07-21 The University Of Queensland Treatment of neurodegenerative diseases using ultrasound and amyloid-beta antibodies
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
WO2023180811A2 (en) 2022-03-22 2023-09-28 Insightec Ltd. Monitoring tissue permeability during ultrasound procedures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622275B (zh) * 2007-01-05 2013-11-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
WO2010004434A2 (en) * 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
ITRM20120383A1 (it) * 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.

Also Published As

Publication number Publication date
CA2894178A1 (en) 2014-06-12
EP2928494A1 (en) 2015-10-14
IL239259A0 (en) 2015-07-30
WO2014089500A1 (en) 2014-06-12
EP2928494A4 (en) 2016-11-02
HK1215673A1 (zh) 2016-09-09
CN105979962A (zh) 2016-09-28
JP2016501247A (ja) 2016-01-18
BR112015013312A2 (pt) 2017-11-14
MX2015007147A (es) 2016-07-26
KR20150127570A (ko) 2015-11-17
AU2013354968A1 (en) 2015-07-16
US20150315267A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
EA201591019A1 (ru) СПОСОБ СНИЖЕНИЯ КОЛИЧЕСТВА АМИЛОИДНЫХ БЛЯШЕК В ГОЛОВНОМ МОЗГЕ ПРИ ПОМОЩИ АНТИ-Aβ АНТИТЕЛ
PH12021550023A1 (en) Humanized anti-tau antibodies
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
CO2018000809A2 (es) Anticuerpos para cd40
TN2017000072A1 (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201590388A1 (ru) Способы лечения таупатии
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201690898A1 (ru) Способы лечения таупатии
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
EA201790192A1 (ru) СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
EA201592203A1 (ru) Способы лечения таупатии
EA201591618A1 (ru) Замещенные имидазопиридазины
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
EA201590720A8 (ru) АНТИ-Flt-1-АНТИТЕЛА В ЛЕЧЕНИИ МЫШЕЧНОЙ ДИСТРОФИИ ДЮШЕНА
EA201600288A1 (ru) Замещенные фенилаланиновые производные
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
EA201990559A1 (ru) Комбинированная терапия